Virios Therapeutics Inc (VIRI) Quote

Conference call May 9th Folks!!

ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update.

The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and asking to be connected to the "Virios Therapeutics Conference Call" using the access code: 739495.

About Virios Therapeutics

Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (“FM”) and Long-COVID (“LC”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndromes, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system. The Company’s lead development candidates are novel, proprietary, fixed dose combinations of an antiviral compound and celecoxib designed to synergistically suppress herpesvirus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 (fixed dosage combination of famciclovir and celecoxib) has been granted fast track designation by the FDA.

For more information, please visit www.virios.com.

Filing:

https://ir.stockpr.com/virios/sec-filings-email/content/0001558370-24-005761/tmb-20240618xdef14a.htm

No doubt.

Yeah man, and VIRI is definitely a buy and hold in my book.👍

That is how these small bio plays work though. You buy the stock expecting that they get bought out by the giant pharmaceuticals like Pfizer, Merck, etc. Virios could be bought out any day or not. But the more successful they are, the greater the chance (not that that is rocket science)

Hmmm a little action today

I’ll be right here waiting no matter how long it takes.😎

Right with you with those thoughts.

I truly believe it’s going to be worth the wait bud😎💰

Mr. Duncan, while at Pfizer he held several executive U.S. and international appointments, including President of Pfizer’s $2B Latin America Operations and SVP of Marketing. His operational teams had accountability for the launches of many pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent, Rebif and Vimpat.

Great color. I’ll be waiting. Thanks!

I truly believe it’s going to be worth the wait bud😎💰

Mr. Duncan, while at Pfizer he held several executive U.S. and international appointments, including President of Pfizer’s $2B Latin America Operations and SVP of Marketing. His operational teams had accountability for the launches of many pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent, Rebif and Vimpat.

It is time for this to take off….

On that note, I added again this am

I believe Greg Duncan Viri CEO mentioned the aim for the first Quarter 2024 to settle a partnership or funding opportunity, let us see if he delivers on time

$VIRI
They keep on highlighting this..are they foreshadowing or begging? 🤔 https://t.co/xtSKqZwBMF— Frank_Benedetto (@FrankieBstock) April 17, 2024

Their tweet has a common theme, I'm taking it as a hint

JAGX average was .07 it crossed .25

Which one? Congratulations

Now .45s added

Added .46s to me stash, these bios have a tendency to go ballistic without notice, like what one of mine did today

My Magic 8 Ball says hell yeah!😎💰

$VIRI
They have been mentioning this repeatedly. Does this hint at a forthcoming deal/opportunity coming? https://t.co/jpJjAoVzxF— Frank_Benedetto (@FrankieBstock) April 11, 2024

Keep bringing the social media posts😎 I have a feeling we’re close to GREATNESS💰

As reported in US News and World Reporthttps://t.co/0q8eMme3FB pic.twitter.com/uKVD3yB8Op— Virios Therapeutics (@ViriosBiotech) April 11, 2024

This needs to stop bleeding

Added a tad more this am

Missed it but ready for more

Here we go Action

True

These Bios are quiet until they are not..

Added .46s !!!

VIRI getting pretty active on X😎💰

pic.twitter.com/aX6b7Jd5AQ— Virios Therapeutics (@ViriosBiotech) April 8, 2024

Me too

Got it, thanks

I added .46s...

Don’t even ask bud😆 That dude is a total 💩 show! VIRI LONG💰

?

Fun one is breaking down in failure again. Not my fault.

Clowns making shiate up? Good clowns

That's a nice target.!!

first target

What's happening at 2:45 .. are you referring to power hour?

better add more before 2.45

Stretchin her leggs! $VIRI

Very nice

Added more .51s

She is going on o be a beauty!

LMAO

Same thing they said last year from .0042 -$2.45

They don't trade up everyday but when they do oh baby!!!!

This POS better hold more volume and continue the trend or it will always poop back to the toilet level.

This is going to be a fun one…. I want to grab more shares over the next month so hopefully we hang around here. Don’t get me wrong, I’ll take a buyout with my current shares I bought but I want more!

Great stuff

Pretty sure that's why we all bought back in.

Grabbed some shares. I hope these guys get taken out by a big bio pharmaceutical company. That is usually the case with these smaller successful bio cos

Good move bud👍 The VIRI CEO knows plenty of people in the pharmaceutical industry, so hopefully he already has people knocking on his door.